ACRIVON THERAPEUTICS INC (ACRV) Stock Income Statement
NASDAQ:ACRV - Nasdaq - US0048901096 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 93.19M | 89.20M | 67.10M | 32.66M | 16.18M | |||
| Research and Development | 67.93M | 63.99M | 46.02M | 23.95M | 13.72M | |||
| Selling, General, and Administrative Expenses | 25.26M | 25.21M | 21.08M | 8.71M | 2.47M | |||
| Operating Income | -93.19M | -89.20M | -67.10M | -32.66M | -16.18M | |||
| Interest Income/Expense | 9.75M | 9.20M | N/A | N/A | 0.00 | |||
| Other Income/Expense | -308.00K | -558.00K | 6.71M | 1.49M | -160.00K | |||
| Non Recurring Items | N/A | N/A | N/A | N/A | 100.00K | |||
| Income Before Taxes | -83.75M | -80.56M | -60.39M | -31.17M | -16.24M | |||
| Net Income | -83.75M | -80.56M | -60.39M | -31.17M | -16.24M | |||
| EBITDA | -92.10M | -88.19M | -66.57M | -32.30M | -16.14M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.22 | -2.38 | -2.74 | -1.42 | -0.78 | |||
| Non GAAP EPS | -2.22 | -2.44 | -2.73 | N/A | N/A | |||
| Statistics | ||||||||
All data in USD